Mirtazapina Mabo (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Mabo, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral formulation for oral use. Classified under ATC code N05CF02, it is prescribed for major depressive disorder in adult patients, aiming to improve mood, sleep, and appetite under medical supervision.

GNH USA supplies Mirtazapina Mabo as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide from its EU‑originated manufacturing sources. The company adheres to stringent quality standards and offers reliable logistics for global distribution.

Mirtazapine is used primarily in the treatment of depressive disorders, targeting mood regulation pathways.

- Major depressive disorder: alleviates depressive symptoms, improves mood, sleep, and appetite in adult patients.

Mirtazapine may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Drowsiness: sedation or sleepiness, especially early in therapy. - Increased appetite: may lead to weight gain. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Agranulocytosis: severe drop in white blood cells. - Hepatotoxicity: liver enzyme elevations or injury. - Severe allergic reactions: rash, swelling, or anaphylaxis.

When prescribing mirtazapine, clinicians should consider several precautionary measures to ensure safe use. - Pregnancy: use only if potential benefit justifies potential risk, as safety data are limited. - Breastfeeding: caution advised; the drug may pass into breast milk. - Elderly patients: start at low dose and monitor for excessive sedation. - Concomitant CNS depressants: may enhance sedative effects; adjust therapy accordingly. - Suicide risk: monitor patients for worsening depression or emergence of suicidal thoughts. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis; avoid concomitant use. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - CNS depressants (benzodiazepines, alcohol): additive sedation. - Anticholinergic agents: may exacerbate dry mouth and constipation. - Serotonergic drugs (SSRIs, SNRIs, tramadol): potential for serotonin syndrome.